Ralph W deVere White, MD

Research output

Research output per year 1973 2021

• 12997 Citations
• 59 h-Index
• 300 Article
• 5 Conference contribution
• 4 Chapter
• 2 Comment/debate
• 4 More
  • 2 Review article
  • 1 Editorial
  • 1 Letter

Research output per year

Research output per year

Search results

• 2021

  Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

  PDXNET Consortium & EurOPDX Consortium, Jan 2021, In: Nature Genetics. 53, 1, p. 86-99 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Heterografts 100%
  • Neoplasms 35%
  • Neoplasm Genes 8%
  • Oligonucleotide Array Sequence Analysis 7%
  • DNA Sequence Analysis 7%
  5 Scopus citations
• 2020

  Germline and somatic DNA repair gene alterations in prostate cancer

  Dall’Era, M. A., McPherson, J. D., Gao, A. C., DeVere White, R. W., Gregg, J. P. & Lara, P. N., Jan 1 2020, (Accepted/In press) In: Cancer.

  Research output: Contribution to journal › Article › peer-review

  • DNA Repair 100%
  • Prostatic Neoplasms 85%
  • Prostate 64%
  • Neoplasm Metastasis 57%
  • Genes 43%
  4 Scopus citations
• 2019

  Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice

  Martin, K. A., Hum, N. R., Sebastian, A., He, W., Siddiqui, S., Ghosh, P. M., Pan, C. X., de Vere White, R. & Loots, G. G., Oct 9 2019, In: International journal of molecular sciences. 20, 20

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Methionine Adenosyltransferase 100%
  • methionine 97%
  • Drug therapy 96%
  • Chemotherapy 92%
  • chemotherapy 89%
  2 Scopus citations
• 2018

  Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy

  Ho, P. Y., Duan, Z., Batra, N., Jilek, J. L., Tu, M. J., Qiu, J. X., Hu, Z., Wun, T., Lara, P. N., deVere White, R. W., Chen, H. & Yu, A., Jun 1 2018, In: Journal of Pharmacology and Experimental Therapeutics. 365, 3, p. 494-506 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Untranslated RNA 100%
  • MicroRNAs 53%
  • recombinant RNA 42%
  • Bioengineering 33%
  • Neoplasms 28%
  24 Scopus citations

• Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988–2015

  Dall'Era, M., deVere White, R. W., Rodriguez, D. & Cress, R. D., Jan 1 2018, (Accepted/In press) In: European Urology Focus.

  Research output: Contribution to journal › Article › peer-review

  • Prostatic Neoplasms 100%
  • Prostate-Specific Antigen 75%
  • Incidence 61%
  • Hispanic Americans 20%
  • Age Groups 15%
  8 Scopus citations

• Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel

  Wang, S., Scharadin, T. M., Zimmermann, M., Malfatti, M. A., Turteltaub, K. W., De Vere White, R., Pan, C. X. & Henderson, P. T., Dec 17 2018, In: Chemical Research in Toxicology. 31, 12, p. 1293-1304 12 p.

  Research output: Contribution to journal › Article › peer-review

  • DNA Adducts 100%
  • Platinum 84%
  • Oxaliplatin 58%
  • Carboplatin 57%
  • Adduct 56%
  6 Scopus citations

• COX-2/sEH dual inhibitor PTUPB potentiates the antitumor efficacy of cisplatin

  Wang, F., Zhang, H., Ma, A. H., Yu, W., Zimmermann, M., Yang, J., Hwang, S. H., Zhu, D., Lin, T. Y., Malfatti, M. A., Turteltaub, K. W., Henderson, P. T., Airhart, S., Hammock, B. D., Yuan, J., De Vere White, R. W. & Pan, C. X., Feb 1 2018, In: Molecular Cancer Therapeutics. 17, 2, p. 474-483 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Epoxide Hydrolases 100%
  • Cyclooxygenase 2 75%
  • Cisplatin 64%
  • gemcitabine 30%
  • Platinum 28%
  17 Scopus citations

• Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

  Wang, M., Yao, L. C., Cheng, M., Cai, D., Martinek, J., Pan, C-X., Shi, W., Ma, A. H., deVere White, R. W., Airhart, S., Liu, E. T., Banchereau, J., Brehm, M. A., Greiner, D. L., Shultz, L. D., Palucka, K. & Keck, J. G., Mar 1 2018, In: FASEB Journal. 32, 3, p. 1537-1549 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Growth Inhibition 100%
  • Cell Death 89%
  • Implant 82%
  • Immunotherapy 73%
  • Antigen 70%
  108 Scopus citations

• Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model

  Long, Q., Lin, T-Y., Huang, Y., Li, X., Ma, A. H., Zhang, H., Carney, R., Airhart, S., Lam, K., deVere White, R. W., Pan, C-X. & Li, Y., Apr 1 2018, In: Nanomedicine: Nanotechnology, Biology, and Medicine. 14, 3, p. 789-799 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Heterografts 100%
  • Signalling Molecule 68%
  • Tumors 55%
  • Urinary Bladder Neoplasms 51%
  • Reactive Oxygen Metabolite 50%
  8 Scopus citations

• Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence

  Yap, S., Brunson, A., Pugashetti, N., Rosemary, R. D. C., Keegan, T. H., deVere White, R. W. & Wun, T., Nov 1 2018, In: Urologic Oncology: Seminars and Original Investigations. 36, 11, p. 498.e1-498.e7

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Drug Therapy 61%
  • Recurrence 59%
  • Survival 23%
  • Logistic Models 13%

• The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long-Term Followup

  Yap, S., Pugashetti, N., Chandrasekar, T., Dall'Era, M., Evans, C. P., Lara, P. N. & deVere White, R. W., Jul 1 2018, In: Urology Practice. 5, 4, p. 305-310 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Muscles 62%
  • Urinary Bladder 62%
  • Drug Therapy 61%
  • Cystectomy 43%
• 2017

  A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer

  Wang, S. S., Zimmermann, M., Zhang, H., Lin, T. Y., Malfatti, M. A., Haack, K., Turteltaub, K. W., Cimino, G. D., de Vere White, R., Pan, C. X. & Henderson, P. T., Aug 1 2017, In: International Journal of Cancer. 141, 3, p. 604-613 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Carboplatin 100%
  • Platinum 93%
  • Non-Small Cell Lung Carcinoma 79%
  • Mass Spectrometry 30%
  • carboplatin-DNA adduct 25%
  6 Scopus citations

• Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models

  Jian, C., Tu, M. J., Ho, P. Y., Duan, Z., Zhang, Q., Qiu, J. X., deVere White, R. W., Wun, T., Lara, P. N., Lam, K., Yu, A. X. & Yu, A., 2017, In: Oncotarget. 8, 19, p. 30742-30755 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Osteosarcoma 100%
  • RNA 66%
  • Neoplasm Metastasis 59%
  • DNA 53%
  • Lung 51%
  15 Scopus citations

• Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells

  Gheibi, P., Zeng, S., Son, K. J., Vu, T., Ma, A. H., Dall'Era, M. A., Yap, S. A., De Vere White, R. W., Pan, C. X. & Revzin, A., Dec 1 2017, In: Scientific Reports. 7, 1, 12277.

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Drug Resistance 95%
  • Heterografts 93%
  • Neoplasms 33%
  • Microfluidics 31%
  15 Scopus citations

• Microdose-induced drug-DNA adducts as biomarkers of chemotherapy resistance in humans and mice

  Zimmermann, M., Wang, S. S., Zhang, H., Lin, T. Y., Malfatti, M. A., Haack, K., Ognibene, T., Yang, H., Airhart, S., Turteltaub, K. W., Cimino, G. D., Tepper, C. G., Drakaki, A., Chamie, K., De Vere White, R., Pan, C. X. & Henderson, P. T., Feb 1 2017, In: Molecular Cancer Therapeutics. 16, 2, p. 376-387 12 p.

  Research output: Contribution to journal › Article › peer-review

  • DNA Adducts 100%
  • Biomarkers 52%
  • Drug Therapy 47%
  • carboplatin-DNA adduct 36%
  • Carboplatin 35%
  18 Scopus citations

• The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: Implications for the use of mTOR inhibitors in advanced prostate cancer

  D'Abronzo, L. S., Bose, S., Crapuchettes, M. E., Beggs, R. E., Vinall, R. L., Tepper, C. G., Siddiqui, S., Mudryj, M., Melgoza, F. U., Durbin-Johnson, B. P., deVere White, R. W. & Ghosh, P. M., Nov 16 2017, In: Oncogene. 36, 46, p. 6359-6373 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Eukaryotic Initiation Factor-4E 100%
  • bicalutamide 75%
  • Androgen Receptors 72%
  • Sirolimus 71%
  • Prostatic Neoplasms 53%
  23 Scopus citations

• The phosphatidylinositol 3-kinase pathway as a potential therapeutic target in bladder cancer

  Zeng, S. X., Zhu, Y., Ma, A. H., Yu, W., Zhang, H., Lin, T-Y., Shi, W., Tepper, C. G., Henderson, P., Airhart, S., Guo, J. M., Xu, C. L., deVere White, R. W. & Pan, C-X., Nov 1 2017, In: Clinical Cancer Research. 23, 21, p. 6580-6591 12 p.

  Research output: Contribution to journal › Article › peer-review

  • 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 100%
  • Phosphatidylinositol 3-Kinase 56%
  • Urinary Bladder Neoplasms 53%
  • Phosphatidylinositol 3-Kinases 24%
  • Heterografts 22%
  24 Scopus citations

• TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies

  Lara, P. N., Heilmann, A. M., Elvin, J. A., Parikh, M., White, R. D. V., Gandour-Edwards, R., Evans, C. P., Pan, C. X., Schrock, A. B., Erlich, R., Ross, J. S., Stephens, P. J., McPherson, J., Miller, V. A. & Ali, S. M., Jan 1 2017, In: JCO Precision Oncology. 2017, 1, p. 1-6 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Prostatic Neoplasms 100%
  • Squamous Cell Carcinoma 63%
  • Adenocarcinoma 59%
  • Gene Fusion 57%
  • Neoplasms 56%
  5 Scopus citations
• 2016

  A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

  Chow, H., Ghosh, P. M., deVere White, R. W., Evans, C. P., Dall'Era, M., Yap, S., Li, Y., Beckett, L. A., Lara, P. N. & Pan, C-X., Jun 15 2016, In: Cancer. 122, 12, p. 1897-1904 8 p.

  Research output: Contribution to journal › Article › peer-review

  • bicalutamide 100%
  • Everolimus 84%
  • Castration 74%
  • Prostatic Neoplasms 53%
  • Clinical Trials 43%
  30 Scopus citations

• Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy

  Vinall, R. L., Tepper, C. G., Ripoll, A. A. Z., Gandour-Edwards, R. F., Durbin-Johnson, B. P., Yap, S., Ghosh, P. M. & deVere White, R. W., Mar 1 2016, In: Genes and Cancer. 7, 3-4, p. 86-97 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Muscles 62%
  • Drug Therapy 61%
  • MicroRNAs 21%
  • Survival Rate 19%
  14 Scopus citations

• Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry

  Lara, J., Brunson, A., Keegan, T. H., Malogolowkin, M., Pan, C-X., Yap, S. & deVere White, R. W., Nov 1 2016, In: Journal of Urology. 196, 5, p. 1378-1382 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Young Adult 84%
  • Registries 82%
  • Survival 57%
  • Neoplasms 33%
  14 Scopus citations

• Diagnostic Microdosing Approach to Study Gemcitabine Resistance

  Scharadin, T. M., Zhang, H., Zimmermann, M., Wang, S., Malfatti, M. A., Cimino, G. D., Turteltaub, K., De Vere White, R., Pan, C. X. & Henderson, P. T., Nov 21 2016, In: Chemical Research in Toxicology. 29, 11, p. 1843-1848 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Microdosing 100%
  • Gemcitabine 81%
  • gemcitabine 60%
  • Resistance 34%
  • DNA 24%
  6 Scopus citations

• Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer

  Pan, A., Zhang, H., Li, Y., Lin, T-Y., Wang, F., Lee, J. S., Cheng, M., Dall'Era, M., Li, T., deVere White, R. W., Pan, C-X. & Lam, K., Sep 19 2016, In: Nanotechnology. 27, 42, 425103.

  Research output: Contribution to journal › Article › peer-review

  • Heterografts 100%
  • Drug delivery 72%
  • Paclitaxel 65%
  • Sodium sulfate 46%
  • Micelles 32%
  14 Scopus citations

• Effect of neoadjuvant chemotherapy on renal function following radical cystectomy: Is there a meaningful impact?

  Chandrasekar, T., Pugashetti, N., Durbin-Johnson, B., Era, M. A. D., Evans, C. P., White, R. W. D. & Yap, S. A., Jan 1 2016, In: Bladder Cancer. 2, 4, p. 441-448 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Cystectomy 100%
  • Drug Therapy 52%
  • Kidney 47%
  • Urinary Bladder 11%
  • Carcinoma 9%
  2 Scopus citations

• Molecular dissection of induced platinum resistance through functional and gene expression analysis in a cell culture model of bladder cancer

  Wang, S., Zhang, H., Scharadin, T. M., Zimmermann, M., Hu, B., Pan, A. W., Vinall, R. L., Lin, T-Y., Cimino, G., Chain, P., Vuyisich, M., Gleasner, C., McMurry, K., Malfatti, M., Turteltaub, K. W., deVere White, R. W., Pan, C-X. & Henderson, P., Jan 1 2016, In: PLoS One. 11, 1, e0146256.

  Research output: Contribution to journal › Article › peer-review

  • urinary bladder neoplasms 100%
  • platinum 80%
  • Platinum 68%
  • Oxaliplatin 63%
  • Urinary Bladder Neoplasms 62%
  13 Scopus citations

• Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer

  Lin, T. Y., Li, Y., Liu, Q., Chen, J. L., Zhang, H., Lac, D., Zhang, H., Ferrara, K. W., Wachsmann-Hogiu, S., Li, T., Airhart, S., deVere White, R., Lam, K. S. & Pan, C. X., Oct 1 2016, In: Biomaterials. 104, p. 339-351 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Theranostics 100%
  • Photodynamic therapy 70%
  • Theranostic Nanomedicine 67%
  • Doxorubicin 53%
  • Urinary Bladder Neoplasms 49%
  42 Scopus citations

• Perioperative Outcomes following Neoadjuvant Chemotherapy and Radical Cystectomy-Is There Room for Improvement?

  Pugashetti, N., Chandrasekar, T., Lurvey, R., Durbin-Johnson, B., Dall'Era, M., deVere White, R. W., Evans, C. P. & Yap, S., 2016, (Accepted/In press) In: Urology Practice.

  Research output: Contribution to journal › Article › peer-review

  • Cystectomy 100%
  • Drug Therapy 52%
  • Patient Readmission 45%
  • Logistic Models 19%
  • Surgical Wound Infection 11%
  1 Scopus citations
• 2015

  Bioengineering novel chimeric microrna-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization

  Wang, W. P., Ho, P. Y., Chen, Q. X., Addepalli, B., Limbach, P. A., Li, M. M., Wu, W. J., Jilek, J. L., Qiu, J. X., Zhang, H. J., Li, T., Wun, T., deVere White, R. W., Lam, K. & Yu, A., Aug 1 2015, In: Journal of Pharmacology and Experimental Therapeutics. 354, 2, p. 131-141 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Bioengineering 100%
  • Prodrugs 84%
  • Transfer RNA 83%
  • MicroRNAs 64%
  • recombinant RNA 31%
  32 Scopus citations

• Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform

  Gandara, D. R., Mack, P., Bult, C., Li, T., Lara, P. N., Riess, J., Astrow, S. H., Gandour-Edwards, R. F., Cooke, D. T., Yoneda, K. Y., Moore, E. H., Pan, C-X., Burich, R. A., David, E., Keck, J. G., Airhart, S., Goodwin, N., deVere White, R. W. & Liu, E. T., May 1 2015, In: Clinical Lung Cancer. 16, 3, p. 165-172 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Genomics 100%
  • Heterografts 88%
  • Neoplasms 31%
  • Non-Small Cell Lung Carcinoma 26%
  • Drug Development 18%
  11 Scopus citations

• Development and characterization of bladder cancer patient- derived xenografts for molecularly guided targeted therapy

  Pan, C. X., Zhang, H., Tepper, C. G., Lin, T. Y., Davis, R. R., Keck, J., Ghosh, P. M., Gill, P., Airhart, S., Bult, C., Gandara, D. R., Liu, E. & De Vere White, R. W., Aug 13 2015, In: PLoS One. 10, 8, e0134346.

  Research output: Contribution to journal › Article › peer-review

  • urinary bladder neoplasms 100%
  • Urinary Bladder Neoplasms 62%
  • Heterografts 58%
  • Lapatinib 56%
  • therapeutics 50%
  49 Scopus citations

• MIR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src

  Shi, X. B., Ma, A. H., Xue, L., Li, M., Nguyen, H. G., Yang, J. C., Tepper, C. G., Gandour-Edwards, R. F., Evans, C. P., Kung, H-J. & deVere White, R. W., Dec 15 2015, In: Cancer Research. 75, 24, p. 5309-5317 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Androgen Receptors 100%
  • Prostatic Neoplasms 73%
  • MDV 3100 68%
  • Down-Regulation 65%
  • Growth 46%
  39 Scopus citations
• 2014

  Legends in urology

  deVere White, R. W., 2014, In: Canadian Journal of Urology. 21, 2, p. 7176-7178 3 p.

  Research output: Contribution to journal › Article › peer-review

• MiR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT

  Kao, C. J., Martiniez, A., Shi, X. B., Yang, J., Evans, C. P., Dobi, A., deVere White, R. W. & Kung, H-J., May 8 2014, In: Oncogene. 33, 19, p. 2495-2503 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Epithelial-Mesenchymal Transition 100%
  • Epidermal Growth Factor 94%
  • Genes 38%
  • Prostatic Neoplasms 33%
  • Neoplasms 31%
  116 Scopus citations

• No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period

  Wu, J. N., Fish, K. M., Evans, C. P., deVere White, R. W. & Dall'Era, M., Mar 15 2014, In: Cancer. 120, 6, p. 818-823 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Prostatic Neoplasms 100%
  • Survival 69%
  • Prostate-Specific Antigen 55%
  • Mortality 27%
  • Multivariate Analysis 25%
  92 Scopus citations

• Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.

  Nguyen, H. G., Yang, J. C., Kung, H-J., Shi, X. B., Tilki, D., Lara, P. N., deVere White, R. W., Gao, A. C. & Evans, C. P., 2014, In: Oncogene. 33, 36, p. 4521-4530 10 p.

  Research output: Contribution to journal › Article › peer-review

  • MDV 3100 100%
  • Castration 75%
  • Autophagy 65%
  • Heterografts 60%
  • Prostatic Neoplasms 53%
  106 Scopus citations

• The role of microRNA in castration-resistant prostate cancer

  Thieu, W., Tilki, D., deVere White, R. W. & Evans, C. P., 2014, In: Urologic Oncology: Seminars and Original Investigations. 32, 5, p. 517-523 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Castration 100%
  • MicroRNAs 76%
  • Prostatic Neoplasms 71%
  • Immunotherapy 8%
  • Systematic Reviews 7%
  23 Scopus citations

• Toward a common therapeutic framework in castration-resistant prostate cancer: A model for urologic oncology and medical oncology interaction

  deVere White, R. W. & Lara, P. N., 2014, In: Urologic Oncology: Seminars and Original Investigations. 32, 4, p. 380-382 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Medical Oncology 100%
  • Urology 94%
  • Castration 93%
  • Prostatic Neoplasms 66%
  • Patient Care 32%
  2 Scopus citations
• 2013

  Functional p53 determines docetaxel sensitivity in prostate cancer cells

  Liu, C., Zhu, Y., Lou, W., Nadiminty, N., Chen, X., Zhou, Q., Shi, X. B., deVere White, R. W. & Gao, A. C., Mar 2013, In: Prostate. 73, 4, p. 418-427 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Docetaxel 100%
  • Prostatic Neoplasms 70%
  • Phosphorylation 19%
  • Small Interfering RNA 9%
  • Cell Death 8%
  75 Scopus citations

• Oncomir miR-125b Suppresses p14^ARF to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer

  Amir, S., Ma, A. H., Shi, X. B., Xue, L., Kung, H-J. & deVere White, R. W., Apr 9 2013, In: PLoS One. 8, 4, e61064.

  Research output: Contribution to journal › Article › peer-review

  • Tumor Suppressor Protein p14ARF 100%
  • prostatic neoplasms 90%
  • MicroRNA 81%
  • apoptosis 60%
  • Prostatic Neoplasms 52%
  63 Scopus citations

• Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells

  Shi, X. B., Xue, L., Ma, A. H., Tepper, C. G., Gandour-Edwards, R. F., Kung, H-J. & deVere White, R. W., Aug 29 2013, In: Oncogene. 32, 35, p. 4130-4138 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Androgen Receptors 100%
  • Prostatic Neoplasms 73%
  • Down-Regulation 32%
  • Neoplasms 29%
  • Growth 23%
  126 Scopus citations

• Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer

  Lin, T. Y., Li, Y. P., Zhang, H., Luo, J. T., Goodwin, N., Gao, T., White, R. D. V., Lam, K. S. & Pan, C. X., Aug 2013, In: Nanomedicine. 8, 8, p. 1239-1251 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Chemotherapy 100%
  • Micelles 94%
  • chemotherapy 89%
  • Tumor 89%
  • Imaging 75%
  29 Scopus citations
• 2012

  Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization

  Mooso, B. A., Vinall, R. L., Tepper, C. G., Savoy, R. M., Cheung, J. P., Singh, S., Siddiqui, S., Wang, Y., Bedolla, R. G., Martinez, A., Mudryj, M., Kung, H-J., deVere White, R. W. & Ghosh, P. M., Dec 2012, In: Endocrine-Related Cancer. 19, 6, p. 759-777 19 p.

  Research output: Contribution to journal › Article › peer-review

  • genistein combined polysaccharide 100%
  • Filamins 73%
  • Androgens 45%
  • Prostatic Neoplasms 39%
  • daidzein 12%
  24 Scopus citations

• Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma

  Vinall, R. L., Kent, M. S. & deVere White, R. W., Oct 2012, In: American Journal of Veterinary Research. 73, 10, p. 1626-1633 8 p.

  Research output: Contribution to journal › Article › peer-review

  • bladder diseases 100%
  • Urinary Bladder Diseases 73%
  • Transitional Cell Carcinoma 56%
  • bladder 53%
  • carcinoma 50%
  15 Scopus citations

• Human ESC self-renewal promoting microRNAs induce epithelial - Mesenchymal transition in hepatocytes by controlling the PTEN and TGFβ tumor suppressor signaling pathways

  Jung, C. J., Iyengar, S., Blahnik, K. R., Jiang, X., Tahimic, C., Torok, N. J., deVere White, R. W., Farnham, P. J. & Zern, M. A., Jul 2012, In: Molecular Cancer Research. 10, 7, p. 979-991 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Cell Self Renewal 100%
  • Human Embryonic Stem Cells 96%
  • Epithelial-Mesenchymal Transition 83%
  • MicroRNAs 67%
  • Hepatocytes 67%
  20 Scopus citations

• Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach

  Zhang, H., Aina, O. H., Lam, K., deVere White, R. W., Evans, C. P., Henderson, P., Lara, P. N., Wang, X., Bassuk, J. A. & Pan, C-X., Sep 2012, In: Urologic Oncology: Seminars and Original Investigations. 30, 5, p. 635-645 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Ligands 73%
  • PLZ4 peptide 25%
  • Heterografts 18%
  • Cell Line 18%
  37 Scopus citations

• Initiation of prostate cancer in mice by Tp53^R270H: Evidence for an alternative molecular progression

  Vinall, R. L., Chen, J. Q., Hubbard, N., Sulaimon, S. S., Shen, M. M., deVere White, R. W. & Borowsky, A. D., Nov 2012, In: DMM Disease Models and Mechanisms. 5, 6, p. 914-920 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Mutation 100%
  • Prostatic Neoplasms 93%
  • Prostatic Intraepithelial Neoplasia 56%
  • Prostate 21%
  • Androgen 21%
  15 Scopus citations

• In vivo testing of a prototype system providing simultaneous white light and near infrared autofluorescence image acquisition for detection of bladder cancer

  Jacobson, M. C., White, R. D. & Demos, S. G., Mar 2012, In: Journal of Biomedical Optics. 17, 3, 036011.

  Research output: Contribution to journal › Article › peer-review

  • bladder 100%
  • Endoscopy 90%
  • Image acquisition 84%
  • Instrumentation 71%
  • cancer 69%
  12 Scopus citations

• MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth

  Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Shi, X. B., Zou, J. X., Chen, H., Zhang, J., Chen, X., Luo, J., deVere White, R. W., Kung, H-J., Evans, C. P. & Gao, A. C., Mar 30 2012, In: PLoS One. 7, 3, e32832.

  Research output: Contribution to journal › Article › peer-review

  • prostatic neoplasms 100%
  • MicroRNA 89%
  • microRNA 74%
  • MicroRNAs 61%
  • Prostatic Neoplasms 58%
  121 Scopus citations

• MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of myc expression in prostate cancer cells

  Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., deVere White, R. W., Kung, H-J., Evans, C. P. & Gao, A. C., Jan 6 2012, In: Journal of Biological Chemistry. 287, 2, p. 1527-1537 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Androgen 100%
  • MicroRNA 97%
  • Androgen Receptors 85%
  • MicroRNAs 67%
  • Prostatic Neoplasms 63%
  141 Scopus citations

• MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status

  Vinall, R. L., Ripoll, A. Z., Wang, S., Pan, C-X. & deVere White, R. W., Jun 1 2012, In: International Journal of Cancer. 130, 11, p. 2526-2538 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Cisplatin 94%
  • Transitional Cell Carcinoma 73%
  • Sirtuin 1 55%
  • Urinary Bladder 50%
  85 Scopus citations